Latest News -Mito Advocacy

Barth Syndrome Foundation, UMDF, and MitoAction leadership were recently notified by Stealth BioTherapeutics that FDA has refused their request...

Updated 3/12/25, 11amLast night, the House approved the continuing resolution — including the 57% CDMRP cut — to fund the...

With the recent election results, we’ve been getting some inquiries about the impact of a second Trump Administration on mitochondrial disease...

UMDF Cosigns Letter to Congress Encouraging End-of-Year Action on Accelerating Kids’ Access to Care Act, Rare Pediatric Disease Priority Review...

FDA Advisory Committee Deems Potential Barth Syndrome Drug “Effective” Earlier this month, an FDA Advisory Committee voted 10-6...